AZD8055, 丝氨酸/苏氨酸蛋白激酶 mTOR 抑制剂

CAS: 1009298-09-2 货号: A408287 分子式: C25H31N5O4 分子量: 465.56 EC号: 836-652-5
有货
级别和纯度: Moligand™ ? Moligand™ —— 阿拉丁的配体和生物活性小分子系列。适用于需要明确小分子工具的受体、通路和结合研究。 10mM in DMSO
储存条件
-80℃储存
运输条件
特低温运输
★
规格
库存
价格
数量
1ml
A408287-1ml
现货 Stock Image
¥409.90
请输入您要添加的产品数量

概述

AZD8055是ATP竞争性mTOR抑制剂,IC50为0.8 nM,比对PI3K和ATM/DNA-PK的抑制性强超过1000倍。

Information

AZD8055 AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy . Pha
In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7\u2009nM and induces significant differences in EFS distribution.

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling.
Cell Data

cell lines:HCT116, A2780, ACHN, MCF7, HL-60, et al.

Concentrations:1 nM - 1 μM

Incubation Time:72 to 96 hours

Powder Purity:≥97%

规格

英文别名
(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
规格或纯度
Moligand™, 10mM in DMSO
英文名称
AZD8055
生化机理
AZD8055 是一种新型 ATP 竞争性 mTOR 抑制剂,在 MDA-MB-468 细胞中的 IC50 为 0.8 nM,对 PI3K 同工酶和 ATM/DNA-PK 具有极好的选择性(∼1000 倍)。AZD8055 可诱导 Caspase 依赖性凋亡,还能诱导自噬。第 1 阶段
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
丝氨酸/苏氨酸蛋白激酶 mTOR 抑制剂
名称和识别符
EC号
836-652-5
分子类型
小分子
Isomeric SMILES
C[C@H]1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOC[C@@H]5C
分子量
465.56
Reaxy-Rn
26042191
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=26042191&ln=

高级数据

产品属性
ALogP 2.6
关联靶点(人)
MTOR Tclin 丝氨酸/苏氨酸蛋白激酶 mTOR(Serine/threonine-protein kinase mTOR) (6 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
安全和危险性(GHS)
象形图
信号词
警告
危险声明

H227: 可燃液体

预防措施声明

P210: 远离热源,热表面,火花,明火和其他点火源。 - 禁止抽烟。

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P370+P378: 火灾时:使用干砂、干粉或抗醇泡沫灭火。

P403+P235: 存放在通风良好的地方。保持低温。

P501: 将内容物/容器送到批准的废物处理厂处理

质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到1个结果

批号(Lot Number) 证书类型 货号
L2214611L2214611 分析证书 A408287
技术文档和文章
溶液计算器

需要帮助选择级别?

我们的级别选择指南涵盖了目录中所有的变体的纯度、稳定剂状态和应用适用性。

查看 Moligand™ 级别指南 →